Cangrelor vs. Ticagrelor for Early Platelet Inhibition in ST-elevation Myocardial Infarction
Status: Not yet recruiting
Phase of Trial: Phase IV
Latest Information Update: 05 Nov 2019
Price : $35 *
At a glance
- Drugs Cangrelor (Primary) ; Ticagrelor (Primary)
- Indications Myocardial infarction
- Focus Therapeutic Use
- Acronyms CanTi
- 02 Nov 2019 This trial has been Discontinued in Denmark, according to European Clinical Trials Database.
- 27 Jun 2018 Planned End Date changed from 1 Aug 2018 to 1 Aug 2019.
- 27 Jun 2018 Planned primary completion date changed from 1 Jun 2018 to 1 Jun 2019.